$0.03
(1.16%)
Add to watchlist
Create an alert
Stocks and Shares ISATempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Company Information
About this company
Key people
Stephen R. Brady
President, Chief Executive Officer, Director
Nicholas Maestas
Chief Financial Officer, Head - Corporate Strategy, Corporate Secretary
Samuel Whiting
Executive Vice President, Chief Medical Officer
Michael Raab
Independent Chairman of the Board
Geoffrey M. Nichol
Independent Director
Christine A. Pellizzari
Independent Director
Ronit Simantov
Independent Director
Click to see more
Key facts
- Shares in issue4.93m
- EPICTPST
- ISINUS87978U2078
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$12.71m
- Employees24
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.